Translation-X is focused on developing innovative therapeutics specifically aimed at addressing Autism Spectrum Disorders (ASD). The company leverages advanced scientific research and methodologies to create effective treatment options that target the unique challenges associated with ASD. Their commitment to understanding the underlying mechanisms of these disorders drives their pipeline of products, which are designed to improve the quality of life for individuals affected by autism.

The technologies employed by Translation-X encompass a range of cutting-edge approaches in drug development and therapeutic interventions. By integrating insights from neuroscience and pharmacology, the company aims to develop novel compounds that can modulate biological pathways relevant to ASD. This multidisciplinary approach not only enhances the potential efficacy of their therapeutics but also positions Translation-X at the forefront of autism research and treatment innovation.

Switzerland

Translation-X is a spin-off project at the Biozentrum, University of Basel. We are developing novel pharmacological tools to reduce core symptoms of autism by targeting RNA translational machinery.

Translation-X

Company Details